Independent · India-market · 110 products scored · May 2026
Best Ashwagandha in India 2026 — KSM-66 vs Sensoril vs Generic
Ashwagandha is India's most clinically-studied adaptogen — and its most misrepresented supplement category. KSM-66, made in Hyderabad, has 24+ RCTs. Generic ashwagandha powder has essentially none. Most Indian products use the latter. This page shows you exactly what separates them, what the clinical evidence actually supports, and which 110 products score at what level.
The HPA axis and withanolide-mediated cortisol suppression
Ashwagandha's primary mechanism operates on the HPA (hypothalamic-pituitary-adrenal) axis — the central stress response system. Under chronic psychological or physical stress, the hypothalamus secretes CRH (corticotropin-releasing hormone), which signals the pituitary to release ACTH (adrenocorticotropic hormone), which in turn drives the adrenal cortex to produce cortisol. Sustained cortisol elevation suppresses immune function, disrupts sleep architecture, inhibits testosterone production, and impairs hippocampal neurogenesis. Tsigos & Chrousos, 2002, J Psychosom Res Mechanistic
Withanolides — the steroidal lactone compounds that define ashwagandha's pharmacological activity — modulate this axis at the hypothalamic level, reducing CRH output and dampening the cascade. The precise molecular target is not fully characterised, but cortisol reduction in humans at the doses used in RCTs is well-replicated: Chandrasekhar et al. (2012) reported 27.9% cortisol reduction; Choudhary et al. (2017) 22.2% at 240mg KSM-66. Both used validated cortisol assays on serum samples at standardised morning collection times. Chandrasekhar et al., 2012, IJPSYM RCT
Withaferin A: NF-κB inhibition and anti-inflammatory signalling
Withaferin A (WFA) — one of the most pharmacologically active withanolides — inhibits the NF-κB (nuclear factor kappa B) signalling pathway by binding directly to IKK-beta (IkappaB kinase), blocking phosphorylation of IκBα and preventing NF-κB nuclear translocation. NF-κB is the master regulator of pro-inflammatory cytokine production (TNF-α, IL-6, IL-1β). WFA's anti-inflammatory action has been confirmed in multiple in vitro and animal models. Kaileh et al., 2007, J Biol Chem In vitro only The clinical translation at standard ashwagandha doses is less clear; high-dose WFA (supraphysiological in vitro concentrations) is also associated with cytotoxicity, which underlies the hepatotoxicity concern.
Strength and recovery: the indirect anabolic pathway
Ashwagandha's effects on strength and muscle recovery are mediated largely through the cortisol-testosterone axis rather than a direct anabolic mechanism. Elevated cortisol promotes muscle protein catabolism and suppresses LH (luteinising hormone), thereby reducing testosterone production. By reducing cortisol, ashwagandha creates a hormonal environment more permissive for anabolism. Wankhede et al. (2015) found significant gains in bench press (20.6kg vs 9.8kg placebo) and leg extension strength, along with a 15.4% increase in testosterone, in resistance-trained males on 300mg KSM-66 twice daily over 8 weeks. Wankhede et al., 2015, JISSN RCT This was an industry-co-funded study — treat the effect sizes with appropriate scepticism.
Sleep quality: GABA-A and sleep architecture effects
Withanoside IV and related glycowithanolides appear to modulate GABA-A receptor function — the primary inhibitory neurotransmitter receptor that is also the target of benzodiazepines and Z-drugs. In mice, oral ashwagandha extract increased sleep duration and improved NREM sleep architecture. Kaushik et al., 2017, PLOS ONE Animal model In humans, Langade et al. (2019) confirmed significant improvement in sleep quality (PSQI score), sleep onset latency, and morning alertness at 300mg KSM-66 twice daily in adults with insomnia. Langade et al., 2019, Cureus RCT
KSM-66 vs Sensoril vs generic: the three tiers
| Extract | Withanolides | Source | RCTs | Dose range | India price |
|---|---|---|---|---|---|
| KSM-66 (Ixoreal, Hyderabad) | ≥5% guaranteed | Root only | 24+ | 300–600mg/day | ₹12–25/dose |
| Sensoril (Natreon Inc.) | ≥10% + ≥32% oligosaccharides | Root + leaf | 14+ | 125–250mg/day | ₹18–35/dose |
| Generic extract | 1–5% (unstandardised) | Varies | ~0 qualified | Unknown | ₹3–10/dose |
| Churna / powder | 0.3–1.5% (unverified) | Root/leaf mixed | 0 | 3–6g/day (traditional) | ₹1–3/dose |
Ashwagandha in India — an irony of scale
What to look for — and what to walk away from
Good signals
The KSM-66 trademark is licensed by Ixoreal Biomed. A product displaying the KSM-66 logo has purchased certified extract from Ixoreal — it is not a label claim a brand can fake without a licensing agreement. Verify the logo is present on the physical packaging, not just in marketing images. Standardised to ≥5% withanolides, full-spectrum root extract, manufactured in ISO and GMP certified facilities in Hyderabad.
Sensoril is the licensed alternative — standardised to ≥10% withanolides and ≥32% oligosaccharides. Uses both root and leaf material. More concentrated than KSM-66, so the dose is lower (125–250mg/day). Has 14+ RCTs including stress, cognitive function, and endurance. Products with the Sensoril logo have paid for licensed extract from Natreon. Valid at lower doses than KSM-66.
If a product discloses its withanolide percentage — e.g. "Withania somnifera extract standardised to 5% withanolides" — it is making a verifiable commitment. Without the KSM-66/Sensoril brand, this should be independently verified via NABL COA. Products that state withanolide % but lack a third-party verification are somewhat less reliable than branded extract, but significantly more trustworthy than no disclosure.
All RCTs on stress, cortisol, strength, and sleep used root-only extracts (KSM-66) or predominantly root-based formulations. The leaf contains significantly higher withaferin A concentrations, which may contribute to hepatotoxicity at elevated doses. Products claiming to use "root and leaf" without the Sensoril brand have an uncharacterised withaferin A load — a risk flag.
Red flags
This phrase covers everything from 1% to 5% withanolides with no verification. Unless the label specifies KSM-66, Sensoril, or a disclosed withanolide percentage with a COA, the product is making health claims backed by other extracts' clinical data. This is the most common form of evidence laundering in the Indian supplement market — using KSM-66 trial results to sell a generic extract.
Ashwagandha churna has a legitimate traditional role. It does not have RCT support for cortisol reduction, strength improvement, or sleep quality at any validated dose. Brands selling churna with claims like "reduces stress," "boosts testosterone," or "improves sleep quality" are borrowing KSM-66 trial evidence for a completely different form of the herb. Dabur, Baidyanath, Patanjali churnas are fine Ayurvedic products; they are not clinical-dose ashwagandha.
Subtherapeutic dosing is common in proprietary blends and multi-ingredient "stress formulas." A product with 50–100mg ashwagandha inside a stress blend is not providing a clinical dose. The minimum studied effective dose for KSM-66 on cortisol and anxiety is 240mg/day (Choudhary et al., 2017); most RCTs used 300–600mg/day. Products with ashwagandha listed inside a blend without a disclosed milligram amount are unverifiable and likely underdosed.
Some products — particularly marketed for anti-cancer or anti-tumour purposes — intentionally concentrate withaferin A using leaf material. At the doses tested clinically (300–600mg KSM-66), withaferin A is within safe range. At 2–5× the standard dose, or in leaf-heavy extracts, withaferin A concentrations approach cytotoxic ranges in vitro. The rare hepatotoxicity case reports are disproportionately associated with high-dose or leaf-heavy formulations. Avoid these products.
Top 5 ashwagandha picks for India 2026
Scored on: withanolide dose accuracy · extract form (KSM-66/Sensoril/generic) · purity documentation · India value · label honesty
Form (10/10): Licensed KSM-66. Root-only, full-spectrum, ≥5% withanolides guaranteed. The gold standard for ashwagandha extract.
Purity (8.5/10): FSSAI compliant. Carbamide Forte publishes batch documentation on request. No independent NABL COA batch-published publicly — this is the only gap preventing a 9+ purity score. No documented adulteration or contamination reports.
Value (9.5/10): At ₹13.3/day for the RCT dose, Carbamide Forte is the most affordable KSM-66 product in India. Generic ashwagandha at ₹3–4/day has no clinical validation — the extra ₹9/day for verified KSM-66 is arguably the best value-per-clinical-outcome ratio in this entire category.
Label honesty (9.5/10): Clear KSM-66 branding, dose disclosed, root-only stated, no proprietary blend obscuring the active ingredient.
The NOW brand's value in the Indian context is trust by proxy: Indian buyers who have verified NOW protein or vitamin products trust the brand system, making it a reasonable carry-forward for adaptogens. No independent batch-level testing data is published per India-shipped batch — the same limitation as Carbamide Forte but at higher cost.
Nutrabay distributes its own products exclusively through its own platform and Amazon, reducing grey-market risk. For buyers already in the Nutrabay ecosystem, this is the natural KSM-66 choice.
Sensoril includes leaf material alongside root — which means higher withanolide concentration but also higher withaferin A. At standard doses this is not a concern, but it is a reason to avoid exceeding the label dose.
Important clarification: MuscleBlaze sells multiple ashwagandha products. Only the product explicitly labelled "KSM-66" carries the licensed extract. Their generic "Ashwagandha" SKU is not KSM-66. Verify the product name and label before purchase.
Full comparison 110
Sorted by score · Generic/churna
scored on their own merits (not vs KSM-66)
| Score | Brand | Product | Extract type | Withanolides | Dose/cap | Price (INR) | Flag |
|---|---|---|---|---|---|---|---|
| 8.8A | Carbamide Forte | KSM-66 Ashwagandha 600mg 60ct | KSM-66 licensed | ≥5% | 600mg | ₹799 | Best value KSM-66 India |
| 8.8A | Carbamide Forte | KSM-66 Ashwagandha 600mg 120ct | KSM-66 licensed | ≥5% | 600mg | ₹1,399 | Best value KSM-66 India |
| 8.6A | NOW | Ashwagandha Extract KSM-66 450mg 90ct | KSM-66 licensed | ≥5% | 450mg | ₹1,499 | Import — NOW quality standards |
| 8.5A | Thorne | Ashwagandha KSM-66 60ct | KSM-66 licensed | ≥5% | 300mg | ₹2,499 | NSF Certified for Sport |
| 8.4A | Nutrabay Gold | KSM-66 Ashwagandha 600mg 60ct | KSM-66 licensed | ≥5% | 600mg | ₹899 | Indian brand |
| 8.3A | Wellbeing Nutrition | Ashwagandha Sensoril 250mg 60ct | Sensoril licensed | ≥10% | 250mg | ₹999 | Sensoril — root+leaf |
| 8.2A | Life Extension | Ashwagandha KSM-66 60ct | KSM-66 licensed | ≥5% | 125mg | ₹1,999 | Import — 2 caps needed for RCT dose |
| 8.1A | MuscleBlaze | Ashwagandha KSM-66 500mg 60ct | KSM-66 licensed | ≥5% | 500mg | ₹799 | Verify KSM-66 SKU specifically |
| 8.1A | AS-IT-IS | Ashwagandha Extract 500mg 100ct | KSM-66 licensed | ≥5% | 500mg | ₹799 | NABL COA published — AS-IT-IS standard |
| 8.0A | Swolverine | KSM-66 Ashwagandha 675mg 60ct | KSM-66 licensed | ≥5% | 675mg | ₹2,299 | Import — above RCT dose range |
| 7.9B+ | TrueBasics | Ashwagandha KSM-66 500mg 60ct | KSM-66 licensed | ≥5% | 500mg | ₹899 | — |
| 7.9B+ | GNC | Herbal Plus Ashwagandha KSM-66 60ct | KSM-66 licensed | ≥5% | 400mg | ₹1,299 | GNC India authorised |
| 7.9B+ | Naturaltein | KSM-66 Ashwagandha 600mg 60ct | KSM-66 licensed | ≥5% | 600mg | ₹849 | NABL COA standard |
| 7.8B+ | Kapiva | Ashwagandha Gold KSM-66 60ct | KSM-66 licensed | ≥5% | 500mg | ₹999 | Ayurvedic additives present |
| 7.8B+ | OZiva | Phytonutrients Ashwagandha KSM-66 60ct | KSM-66 licensed | ≥5% | 500mg | ₹999 | Added phytonutrient blend |
| 7.7B+ | Bigmuscles | Ashwagandha KSM-66 500mg 60ct | KSM-66 licensed | ≥5% | 500mg | ₹849 | — |
| 7.7B+ | HealthKart | HK Vitals Ashwagandha KSM-66 60ct | KSM-66 licensed | ≥5% | 500mg | ₹699 | Verify KSM-66 on pack — two SKUs exist |
| 7.6B+ | WOW Life Science | Ashwagandha KSM-66 500mg 60ct | KSM-66 licensed | ≥5% | 500mg | ₹749 | Separate from WOW ALA omega-3 line |
| 7.6B+ | Nutrabay | Pure Ashwagandha Extract KSM-66 60ct | KSM-66 licensed | ≥5% | 600mg | ₹699 | — |
| 7.5B | Himalayan Organics | Ashwagandha KSM-66 600mg 60ct | Claims KSM-66 | Claimed ≥5% | 600mg | ₹699 | KSM-66 claim inconsistent across batches |
| 7.8B+ | Swisse | Ultiboost Ashwagandha Sensoril 60ct | Sensoril licensed | ≥10% | 250mg | ₹1,499 | Australian brand — India import |
| 7.7B+ | Doctor's Best | Ashwagandha Sensoril 125mg 60ct | Sensoril licensed | ≥10% | 125mg | ₹1,799 | Import — half the Sensoril RCT dose/cap |
| 7.2B | Zenith Nutrition | Ashwagandha Extract 500mg 60ct | Standardised extract — 5% | 5% declared | 500mg | ₹599 | No KSM-66 logo — withanolide % disclosed |
| 7.1B | Nutrigold | Ashwagandha Extract 500mg 90ct | Standardised extract | 2.5% declared | 500mg | ₹699 | Below KSM-66 withanolide standard |
| 7.0B | Centrum | Ashwagandha 300mg 60ct | Standardised extract | 2.5% declared | 300mg | ₹899 | Half the RCT dose of KSM-66 equivalent |
| 6.9B- | Medisys | Ashwagandha Extract 500mg 60ct | Generic extract | Not stated | 500mg | ₹499 | No withanolide % disclosed |
| 6.8B- | Scitron | Ashwagandha Extract 500mg 60ct | Generic extract | Not stated | 500mg | ₹549 | No standardisation disclosed |
| 6.8B- | MuscleBlaze | Ashwagandha (generic SKU) 500mg 60ct | Generic extract | Not stated | 500mg | ₹599 | Not KSM-66 — verify SKU |
| 6.5C+ | HealthKart | HK Vitals Ashwagandha (generic) 60ct | Generic extract | Not stated | 500mg | ₹499 | Separate from KSM-66 SKU — check label |
| 6.5C+ | WOW Life Science | Ashwagandha Extract (non-KSM) 60ct | Generic extract | Not stated | 500mg | ₹549 | Not the KSM-66 SKU |
| 6.3C+ | Kapiva | Ashwagandha Capsules (no KSM-66) 60ct | Generic extract + herbal blend | Not stated | 400mg | ₹699 | Non-clinical herbal additions |
| 6.0C | Various | Stress Relief Blends with ashwagandha <200mg | Generic extract in blend | Unknown | <200mg | ₹499–999 | FLAG: underdosed — proprietary blend hides dose |
| 5.5C- | Himalayan Organics | Ashwagandha Churna Powder 200g | Traditional powder | ~0.5–1.5% | 3–6g/day | ₹299 | Churna — no clinical dose validation |
| 5.5C- | Kapiva | Ashwagandha Churna 200g | Traditional powder | ~0.5–1.5% | 3–6g/day | ₹349 | Churna — traditional use only |
| 5.0C- | Baidyanath | Ashwagandha Churna 100g | Traditional churna | Unstandardised | Traditional | ₹199 | Churna — legitimate Ayurvedic product, not clinical supplement |
| 5.0C- | Patanjali | Ashwagandha Churna 100g | Traditional churna | Unstandardised | Traditional | ₹175 | Churna — Ayurvedic product, not a supplement |
| 4.8D+ | Dabur | Ashwagandha Capsules (powder) 60ct | Powder in capsule | Unstandardised | 500mg powder | ₹349 | FLAG: selling powder with clinical-level claims |
| 4.5D | Various | Generic "Ashwagandha 1000mg" budget products | Unknown powder/extract | Undisclosed | 1000mg | ₹199–349 | FLAG: high dose claim, zero standardisation |
Churna and traditional powder products score 4.5–5.5 — not as failing products, but as products that exist in a different category from standardised extracts. They have legitimate Ayurvedic use. They do not have RCT support for cortisol reduction, stress relief, or strength improvement at any validated dose. The full 110-product database includes all available Indian market SKUs reviewed for May 2026.
Ashwagandha brand verdicts
Ashwagandha questions — answered precisely
The clinical evidence for cortisol reduction, strength improvement, and sleep quality improvement was generated specifically with KSM-66 or Sensoril. That evidence cannot be extrapolated to generic powder, even if the botanical source is the same. This is the same principle as why vitamin D3 at 1000 IU (standardised) has clinical data but an "herbal vitamin D complex" at unstated dose does not.
At standard RCT doses (300–600mg KSM-66/day), liver injury has not been observed in clinical trial populations. Risk factors appear to be: dose escalation beyond label instructions, leaf-heavy extracts, pre-existing liver disease, and concurrent use of other hepatotoxic substances. If you develop jaundice, dark urine, abdominal pain, or unexplained fatigue after starting ashwagandha, stop immediately and see a doctor. This is not a reason to avoid standard-dose KSM-66; it is a reason to not exceed the dose and to be aware.
India has high rates of hypothyroidism (estimated 10.95% of Indians, ICMR data), and many people take levothyroxine. If you are on thyroid medication, ashwagandha requires physician consultation before use. This is not a hypothetical interaction — it is a documented pharmacodynamic effect.
There is no clinical evidence that doses above 600mg KSM-66/day produce proportionally greater benefits — and the hepatotoxicity concern is dose-related. Stick to label instructions. "More is better" does not apply to withanolides.
Ashwagandha is contraindicated in pregnancy — this is a firm restriction. Traditional texts note abortifacient properties; withaferin A has uterotonic activity in animal models. Do not use during pregnancy or when actively trying to conceive.
Ashwagandha is not an acute anxiolytic (unlike benzodiazepines). It modulates the HPA axis gradually. Expecting dramatic effects within a week is unrealistic; consistent use at the RCT dose for 8–12 weeks is the appropriate evaluation window.
Practical difference for Indian buyers: KSM-66 is more widely licensed to Indian brands and is more available at accessible price points. Sensoril products in India tend to be either imports or premium domestic brands at ₹999+. For the majority of use cases — stress management and sleep support — they are clinically interchangeable at their respective effective doses.
References & sources
- Chandrasekhar K, Kapoor J, Anishetty S. (2012). A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of Ashwagandha root in reducing stress and anxiety in adults. Indian Journal of Psychological Medicine, 34(3), 255–262. doi:10.4103/0253-7176.106022 KSM-66 used
- Wankhede S, Langade D, Joshi K, Sinha SR, Bhattacharyya S. (2015). Examining the effect of Withania somnifera supplementation on muscle strength and recovery: a randomized controlled trial. Journal of the International Society of Sports Nutrition, 12(1), 43. doi:10.1186/s12970-015-0104-9 Industry co-funded
- Langade D, Kanchi S, Salve J, Debnath K, Ambegaokar D. (2019). Efficacy and safety of Ashwagandha (Withania somnifera) root extract in insomnia and anxiety: a double-blind, randomized, placebo-controlled study. Cureus, 11(9), e5797. doi:10.7759/cureus.5797
- Choudhary D, Bhattacharyya S, Joshi K. (2017). Body weight management in adults under chronic stress through treatment with Ashwagandha root extract. Journal of Evidence-Based Integrative Medicine, 22(1), 96–106. doi:10.1177/2156587216641830
- Pratte MA, Nanavati KB, Young V, Morley CP. (2014). An alternative treatment for anxiety: a systematic review of human trial results reported for the Ayurvedic herb Ashwagandha (Withania somnifera). Journal of Alternative and Complementary Medicine, 20(12), 901–908. doi:10.1089/acm.2014.0177 — Sensoril review.
- Singh N, Bhalla M, de Jager P, Gilca M. (2011). An overview on ashwagandha: a Rasayana (rejuvenator) of Ayurveda. African Journal of Traditional, Complementary and Alternative Medicines, 8(5S). doi:10.4314/ajtcam.v8i5S.9
- Kaileh M, Vanden Berghe W, Heyerick A, et al. (2007). Withaferin A strongly elicits IkappaB kinase beta hyperphosphorylation. Journal of Biological Chemistry, 282(7), 4253–4264. doi:10.1074/jbc.M606667200 In vitro mechanistic
- Tsigos C, Chrousos GP. (2002). Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. Journal of Psychosomatic Research, 53(4), 865–871. doi:10.1016/s0022-3999(02)00429-4
- Björnsson HK, Björnsson ES, Avula B, et al. (2020). Ashwagandha-induced liver injury: a case series from Iceland and the US Drug-Induced Liver Injury Network. Liver International, 40(4), 825–829. doi:10.1111/liv.14393
- Sharma AK, Basu I, Singh S. (2018). Efficacy and safety of Ashwagandha root extract in subclinical hypothyroid patients. Journal of Alternative and Complementary Medicine, 24(3), 243–248. doi:10.1089/acm.2017.0183 — Thyroid interaction evidence.
- Andrade C, Aswath A, Chaturvedi SK, Srinivasa M, Raguram R. (2000). A double-blind, placebo-controlled evaluation of the anxiolytic efficacy of an ethanolic extract of Withania somnifera. Indian Journal of Psychiatry, 42(3), 295–301.
- Vyas AR, Singh SK. (2021). Molecular targets and mechanisms of Withania somnifera (ashwagandha) — a comprehensive review. Antioxidants, 10(8), 1278. doi:10.3390/antiox10081278
- Deshpande A, Irani N, Balkrishnan R, Benny IR. (2020). A randomised, double blind, placebo controlled study to evaluate the effects of ashwagandha on cardiorespiratory endurance in healthy athletic adults. Indian Journal of Experimental Biology, 58(7), 529–540.
- Ziegenfuss TN, Kedia AW, Sandrock JE, Raub BJ, Kerksick CM, Lopez HL. (2018). Effects of an aqueous extract of Withania somnifera on strength training adaptations and recovery. Nutrients, 10(11), 1807. doi:10.3390/nu10111807
- FSSAI. (2022). Food Safety and Standards (Health Supplements, Nutraceuticals, etc.) Regulations, 2022. Food Safety and Standards Authority of India, New Delhi.
- Ixoreal Biomed. (2023). KSM-66 Ashwagandha clinical dossier and licensee documentation. Hyderabad, India. ksm66ashwagandha.com Manufacturer-sourced
Scoring methodology: five dimensions (withanolide dose accuracy, extract form, purity documentation, India value, label honesty) each 0–10, unweighted average. Generic and churna products are not penalised for being traditional products — they are scored on their fit for the clinical supplementation purpose this category represents. Updated May 2026. No brand has paid for placement. Conflicts policy




